Compare Abeona Therapeutics Inc (ABEO) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lowe`s Companies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Lowe`s Companies Inc trades at $213.28 (market cap $123.86B). The key difference: Lowe`s Companies Inc is far larger — about 331.8× Abeona Therapeutics Inc's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | LOW | |
|---|---|---|
Market Cap | $373.32M | $123.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $287.39 |
52-Week Low | $4.17 | $206.62 |
Enterprise Value | $228.22M | $165.61B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Lowe's (LOW) trades at $220.9, down 2.9% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 60.79% buy rating from analysts support optimism, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. The stock's P/E of 18.92 and net income margin of 7.51% reflect solid profitability, while dividend increases counter earlier Wall Street skepticism about payout sustainability.
The outlook is positive with a $260.88 consensus price target, but risks include high debt levels, competitive pressure from Home Depot, and macroeconomic sensitivity. Earnings growth and professional market expansion are key catalysts, though inflation and housing market softness pose headwinds for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
